Fennell DA, Ewings S, Ottensmeier C, Califano R, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530-1540.
PMID: 34656227